文献速递浆细胞疾病

基于衰弱分层的减剂量来那度胺-地塞米松方案治疗老年不适合移植初诊多发性骨髓瘤的前瞻性多中心II期研究

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.
PubMed 文献 · Br J Haematol · 2026-07-03

该研究采用修订版骨髓瘤共病指数(R-MCI)对≥70岁不适合移植的初诊多发性骨髓瘤患者进行衰弱分层,中间fit组(R-MCI 4-6)接受来那度胺25mg+地塞米松20mg,衰弱组(R-MCI≥7)接受来那度胺15mg+地塞米松10mg。70例入组(69例可评估,中位年龄80岁),总缓解率86.9%,2年无进展生存率37.4%,2年总生存率63.0%,中间fit组与衰弱组间无显著差异,毒性可管理。

要点

  • R-MCI分层指导的减剂量Rd方案在老年不适合移植NDMM中总缓解率达86.9%。
  • 2年PFS率37.4%,2年OS率63.0%,中间fit与衰弱组间无显著差异。
  • 衰弱组3级及以上中性粒细胞减少发生率40.6%,毒性总体可管理。

核心结论

  • 基于衰弱分层的减剂量Rd方案在老年不适合移植NDMM中产生高缓解率和有临床意义的生存获益,毒性可管理。
  • 探索性分析提示衰弱患者减量起始治疗后结局可能接近中间fit患者,需更大样本前瞻性研究确认。

研究设计与样本

  • 前瞻性多中心II期研究,纳入≥70岁不适合移植的初诊多发性骨髓瘤患者,用R-MCI分为中间fit(4-6分)和衰弱(≥7分)两组。
  • 共70例入组,69例可评估,中位年龄80岁,中间fit占54%,衰弱占46%。
  • 中间fit组起始来那度胺25mg+地塞米松20mg,衰弱组起始来那度胺15mg+地塞米松10mg。
  • 主要终点为2年无进展生存率,次要终点包括总生存、总缓解率和安全性。

主要发现

  • 总缓解率为86.9%,两组≥非常好的部分缓解率均约36%。
  • 2年无进展生存率为37.4%(95%CI 26.9%-57.8%),中位无进展生存期15.6个月。
  • 2年总生存率为63.0%(95%CI 51.6%-77.0%)。
  • 探索性分析中中间fit组与衰弱组在生存结局上无统计学显著差异。
  • 中间fit组和衰弱组3级及以上中性粒细胞减少发生率分别为24.3%和40.6%,3级及以上感染并发症发生率分别为10.8%和12.5%,组间无显著差异。

关键数值与推荐

  • 衰弱分层采用修订版骨髓瘤共病指数(R-MCI):中间fit为4-6分,衰弱为≥7分。
  • 中间fit组起始剂量:来那度胺25mg+地塞米松20mg;衰弱组起始剂量:来那度胺15mg+地塞米松10mg。

临床怎么用

  • 对≥70岁不适合移植的初诊多发性骨髓瘤患者,可依据R-MCI衰弱分层选择减剂量来那度胺-地塞米松起始治疗。
  • 衰弱患者采用减量起始的Rd方案可获得与中间fit患者相近的缓解和生存,且毒性可管理。

局限性

  • 本研究为II期探索性分析,样本量有限(70例入组),组间比较未进行效能计算。
  • 衰弱组与中间fit组结局差异需在足够效能的 prospective 研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Elderly transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) often cannot tolerate standard-dose lenalidomide-dexamethasone (Rd), leading to frequent dose reductions. We evaluated an upfront frailty-adapted Rd dosing strategy using the revised Myeloma Comorbidity Index (R-MCI) in this frail population. In a multicentre phase II trial, patients ≥70 years classified as intermediate-fit (R-MCI 4-6) or frail (R-MCI ≥7) received Rd with starting doses stratified by frailty (intermediate-fit: lenalidomide 25 mg + dexamethasone 20 mg; frail: lenalidomide 15 mg + dexamethasone 10 mg). Two-year progression-free survival (PFS) was the primary end-point. Secondary end-points included overall survival (OS), overall response rate (ORR) and safety. Among 70 enrolled patients (69 evaluable; median age 80), 54% were intermediate-fit and 46% frail. ORR was 86.9%, with ≥VGPR (very good partial response) in ~36% of both groups. Two-year PFS was 37.4% (95% confidence interval [CI]: 26.9%-57.8%; median PFS 15.6 months) and 2-year OS was 63.0% (95% CI: 51.6%-77.0%), with no statistically significant differences between intermediate-fit and frail patients in this exploratory analysis. Grade ≥3 neutropenia occurred in 24.3% and 40.6% of intermediate-fit and frail patients, respectively, while grade ≥3 infectious complications were observed in 10.8% and 12.5%, respectively, without significant differences between groups. The frailty-guided, dose-attenuated Rd regimen in elderly unfit NDMM yielded high response rates and clinically meaningful survival with manageable toxicity. These exploratory findings suggest that frail patients may achieve outcomes approaching those of intermediate-fit patients despite reduced starting doses, warranting confirmation in adequately powered prospective studies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jung SH, Kim D, Lee JJ, et al. Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma. Br J Haematol. 2026. PMID: 42397033. doi:10.1111/bjh.70663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。